Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer

被引：0
|
作者：
Nguyen, Nicholas D. [1 ]
Yu, Meifang [1 ]
Fujimoto, Tara N. [1 ]
Delahoussaye, Abagail [1 ]
Huang, Yanqing [1 ]
Estrada, Manuel A. [1 ]
Taniguchi, Cullen M. [1 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-555
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
555
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer
    Wolfe, Adam R.
    Robb, Ryan
    Hegazi, Ahmad
    Abushahin, Laith
    Yang, Linlin
    Shyu, Duan-Liang
    Trevino, Jose G.
    Cruz-Monserrate, Zobeida
    Jacob, John R.
    Palanichamy, Kamalakannan
    Chakravarti, Arnab
    Williams, Terence M.
    CLINICAL CANCER RESEARCH, 2021, 27 (02) : 554 - 565
  • [2] Synergy of water soluble prodrug triptolide (minnelide) with gemcitabine and nab-paclitaxel in pancreatic cancer.
    Dudeja, Vikas
    Modi, Shrey
    Giri, Bhuwan
    Majumder, Kaustav
    Banerjee, Sulagna
    Saluja, Ashok
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [3] A modified regimen of nab-paclitaxel and gemcitabine in advanced pancreatic cancer
    Osman, M. A. M.
    McDermott, R.
    Fennelly, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [4] Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
    Von Hoff, Daniel D.
    Ervin, Thomas
    Arena, Francis P.
    Chiorean, E. Gabriela
    Infante, Jeffrey
    Moore, Malcolm
    Seay, Thomas
    Tjulandin, Sergei A.
    Ma, Wen Wee
    Saleh, Mansoor N.
    Harris, Marion
    Reni, Michele
    Dowden, Scot
    Laheru, Daniel
    Bahary, Nathan
    Ramanathan, Ramesh K.
    Tabernero, Josep
    Hidalgo, Manuel
    Goldstein, David
    Van Cutsem, Eric
    Wei, Xinyu
    Iglesias, Jose
    Renschler, Markus F.
    NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (18): : 1691 - 1703
  • [5] Nab-paclitaxel and gemcitabine for the treatment of patients with metastatic pancreatic cancer
    Borazanci, Erkut
    Von Hoff, Daniel D.
    EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY, 2014, 8 (07) : 739 - 747
  • [6] Effect of Preoperative Nab-paclitaxel and Gemcitabine on Pancreatic Cancer Stroma
    Ishido, K.
    Kimura, N.
    Wakiya, T.
    Nagase, H.
    Odagiri, T.
    Mitsuhashi, Y.
    Goto, S.
    Yoshizawa, T.
    Kijima, H.
    Hakamada, K.
    PANCREAS, 2019, 48 (10) : 1451 - 1451
  • [7] Co-treatment with gemcitabine and nab-paclitaxel exerts additive effects on pancreatic cancer cell death
    Passacantilli, Ilaria
    Panzeri, Valentina
    Terracciano, Francesca
    Delle Fave, Gianfranco
    Sette, Claudio
    Capurso, Gabriele
    ONCOLOGY REPORTS, 2018, 39 (04) : 1984 - 1990
  • [8] Nab-Paclitaxel as new Therapeutic Option for Pancreatic Cancer
    Michl, P.
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2013, 51 (11): : 1329 - 1330
  • [9] The retrospective analysis of gemcitabine plus nab-paclitaxel in advanced pancreatic cancer
    Ueno, M.
    Kobayashi, S.
    Ohkawa, S.
    Tezuka, S.
    Moriya, S.
    Morimoto, M.
    ANNALS OF ONCOLOGY, 2015, 26 : 67 - 67
  • [10] Inhibition of ERK by LY3214996 augments nab-paclitaxel and gemcitabine combination chemotherapy efficacy in preclinical models of pancreatic cancer
    Bhagwat, Shripad V.
    Wu, Wenjuan
    Zhao, Baohui
    Shen, Weihua
    Kindler, Lisa
    Stephens, Jennifer
    Manro, Jason
    McMillen, William
    Joseph, Sajan
    Peng, Sheng-Bin
    Tiu, Ramon V.
    CANCER RESEARCH, 2019, 79 (13)
12345